Immune-Onc Therapeutics

Immune-Onc Therapeutics develops therapeutic antibodies that target myeloid cell surface proteins to enhance the efficacy of immunotherapy for blood cancers and solid tumors. By modulating or depleting specific myeloid cell subsets, the company aims to improve treatment outcomes for the majority of cancer patients who currently do not respond to existing therapies.

Traction 10/10

Palo Alto, United States · HQ

Founded 2016193K+ followers

Biotechnology

Updated 23 months ago

Funding

Raised to date

$138.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

1 founder

BJ Snider

President/CEO

Product

Problem

Existing cancer immunotherapies, such as T-cell checkpoint inhibitors, are ineffective in a large percentage of patients, particularly those with solid tumors and blood cancers like acute myeloid leukemia (AML). These therapies often fail because they do not adequately address the immunosuppressive effects of myeloid cells within the tumor microenvironment.

Solution

Immune-Onc Therapeutics is developing a pipeline of novel therapeutic antibodies designed to modulate or deplete specific subsets of myeloid cells. By targeting myeloid cell surface proteins, these antibodies aim to reprogram the tumor microenvironment, enhance anti-tumor immunity, and improve treatment outcomes for patients who do not respond to current immunotherapies. The company's approach seeks to unlock the full potential of the immune system to fight cancer by addressing the suppressive roles of myeloid cells in both solid tumors and hematological malignancies.

Target Audience

The primary target audience includes cancer patients with solid tumors and blood cancers who are not responsive to existing immunotherapies, as well as researchers and clinicians in the fields of oncology and immunology.

Features

Antibodies targeting specific myeloid cell surface proteins to modulate immune responses
Focus on modulating or depleting myeloid cell subsets involved in disease pathogenesis
Development of immunomodulatory agents for the treatment of autoimmune diseases and cancers
Aims to enhance the efficacy of existing immunotherapies